Immunicum has announced the appointment of Lotta Ferm as Chief Financial Officer (CFO) effective as of November 1, 2021.
Lotta Ferm has been acting as Immunicum’s interim CFO since February of this year and will continue to lead the company’s finance and HR activities.
“Since her appointment as interim CFO, Lotta has been responsible for synergizing the finance, administrative and HR organization following the merger with DCprime, to ensure the smooth integration of both companies in an effective way,” says Erik Manting, Chief Executive Officer of Immunicum. “Lotta’s extensive experience in finance and controlling will continue to play an important role for Immunicum and we are excited to have her as a permanent member of the leadership team.”
Lotta Ferm brings to Immunicum nearly 30 years of finance and controlling experience, the company states. Prior to joining Immunicum, she held senior management positions at Doktor24 Healthcare AB and Medivir AB in the healthcare and life science sectors. In addition, she has held CFO, Head of Finance and Head of Controlling positions leading a range of corporate finance accounting functions. She holds degrees in Business Administration and Economics from Kristianstad University and Växjö University in Sweden.
“With multiple upcoming value drivers for the company’s lead programs, I look forward to continue advancing Immunicum’s financial and business objectives that will support the establishment of a leading cell-based immunotherapy platform with the potential to change the standard of care for cancer patients,” says Lotta Ferm.
Photo of Lotta Ferm: Immunicum